NCT00107653 - Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. | Biotech Hunter

Enrollment

569

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Ribavirin

1000-1200mg po daily for 48 weeks

DRUG

Peginterferon alfa-2a

180 micrograms sc/week for 48 weeks

DRUG

Ribavirin

1000-1200mg po daily for 48 weeks

DRUG

Peginterferon alfa-2a

180 micrograms sc/week for 48 weeks

Trial Locations (60)

10029

New York

11358

Bayside

14618

Rochester

19107

Philadelphia

19141

Philadelphia

21205

Baltimore

22031

Fairfax

28304

Fayetteville

30106

Austell

33125

Miami

33162

North Miami Beach

33324

Plantation

33428

Boca Raton

34209

Bradenton

37211

Nashville

46202

Indianapolis

60031

Gurnee

60612

Chicago

60637

Chicago

63110

St Louis

70115

New Orleans

70890

Baton Rouge

75203

Dallas

76107

Fort Worth

77030

Houston

77090

Houston

77555

Galveston

78215

San Antonio

78258

San Antonio

81008

Pueblo

84121

Salt Lake City

85259

Scottsdale

85712

Tucson

90022

Los Angeles

90033

Los Angeles

90095

Los Angeles

92123

San Diego

92154

San Diego

92161

San Diego

92373

Redlands

92404

San Bernardino

92708

Fountain Valley

92801

Anaheim

93003

Ventura

93401

San Luis Obispo

93534

Lancaster

93721

Fresno

94110

San Francisco

95817

Sacramento

98133

Seattle

98405

Tacoma

94304-1509

Palo Alto

92103-8465

San Diego

01702

Framingham

01655

Worcester

08360

Vineland

27599-7584

Chapel Hill

78234-3879

Fort Sam Houston

00716

Ponce

00909

Santurce

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY